Shield Therapeutics' Iron Deficiency Drug Lands Indication Extension in US

05:23 AM EST, 12/22/2025 (MT Newswires) -- Shield Therapeutics (STX.L) said Monday that the US Food and Drug Administration approved the extension of the indication for its iron deficiency treatment drug ACCRUFeR to include pediatric patients aged 10 and above. The approval follows a late-stage pediatric clinical trial, which showed positive results of the new oral liquid pediatric formulation in patients aged one month and above with iron deficiency. The British pharmaceutical company intends to apply for a further indication extension to include children one month and above in conjunction with the submission of a new drug application for a new pediatric formulation, ferric maltol suspension.